Vaccine coverage, antibodies against measles, mumps, rubella, hepatitis B in inflammatory bowel disease and juvenile idiopathic arthritis children

Table 1 Demographic characteristics of patients with inflammatory bowel disease and juvenile idiopathic arthritis included in the study, n (%)/median (25^th-75^th percentiles)

Parameter	IBD (n = 97)	JIA (n = 170)	P value
Sex (females)	45 (46.4)	115 (67.7)	< 0.001
Age of the inclusion in the study	14.0 (11.0-16.2)	11.4 (7.6-14.8)	0.03
Age of the disease onset	11.0 (6.0-14.0)	6.0 (3.7-9.0)	0.01
Biological immunosuppressive treatment at study inclusion	88 (51.8)	32 (33.0)	< 0.0001
Immunosuppressive therapy at the time of the study	81 (83.5)	154 (90.6)	0.09

IBD: Inflammatory bowel disease; JIA: Juvenile idiopathic arthritis.

Table 2 Post-vaccination immunity against measles, mumps, rubella, and hepatitis B in patients with inflammatory bowel disease and juvenile idiopathic arthritis, n (%)/median (25^th-75^th percentiles)

Parameter	IBD (n = 97)	JIA (n = 170)	P value
Antibodies against measles, IgG, GM, (IU/mL)	0.15 (0.0-0.35)	0.21 (0.04-0.53)	< 0.001
Complete vaccination against measles for age1	62 (63.9)	95 (55.9)	0.200
Patients with protective levels of antibodies against measles	41 (47.7)	98 (57.7)	0.016
Antibodies against mumps, IgG, GM, (IU/mL)	2.8 (0.9-5.0)	2.9 (1.3-5.3)	0.570
Complete vaccination against mumps for age1	69 (71.1)	95 (55.8)	0.014
Patients with protective levels of antibodies against mumps	73 (75.3)	96 (56.5)	0.003
Antibodies against rubella, IgG, GM	32 (0.0-52.0)	87.3 (45.3-198.3)	< 0.0001
Complete vaccination against rubella for age1	31 (32.0)	75 (44.1)	0.051
Patients with protective levels of antibodies against rubella	64 (74.4)	168 (98.2)	< 0.0001
Complete vaccination against hepatitis B for age1	78 (80.4)	163 (95.9)	0.00004
Patients with protective levels of antibodies against hepatitis B	39 (44.8)	85 (50.0)	0.432
Antibodies against hepatitis B, IgG, GM	0 (0-30)	9.3 (0.03-41.9)	0.024
Patients whose anti-vaccine antibody levels was detected before the treatment	4 (14.3)
Vaccine-associated adverse events anytime
No	85 (88.5)
Fever	4 (4.2)
Injection site reaction	6 (6.2)
IBD flare	1 (1.0)

¹According to the National vaccination schedule to the age.

IBD: Inflammatory bowel disease; JIA: Juvenile idiopathic arthritis.